JP2018526428A - 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 - Google Patents

養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 Download PDF

Info

Publication number
JP2018526428A
JP2018526428A JP2018513549A JP2018513549A JP2018526428A JP 2018526428 A JP2018526428 A JP 2018526428A JP 2018513549 A JP2018513549 A JP 2018513549A JP 2018513549 A JP2018513549 A JP 2018513549A JP 2018526428 A JP2018526428 A JP 2018526428A
Authority
JP
Japan
Prior art keywords
cancer
patient
virus
lymphocytes
oncolytic virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018513549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526428A5 (enExample
Inventor
ウッド ギャリー
ウッド ギャリー
ハラルド ストリッツカー ジョッケン
ハラルド ストリッツカー ジョッケン
Original Assignee
ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー
ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー, ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー filed Critical ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー
Publication of JP2018526428A publication Critical patent/JP2018526428A/ja
Publication of JP2018526428A5 publication Critical patent/JP2018526428A5/ja
Priority to JP2021147640A priority Critical patent/JP2022003043A/ja
Priority to JP2023176751A priority patent/JP2023176003A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018513549A 2015-09-09 2016-09-09 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法 Withdrawn JP2018526428A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021147640A JP2022003043A (ja) 2015-09-09 2021-09-10 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2023176751A JP2023176003A (ja) 2015-09-09 2023-10-12 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562216046P 2015-09-09 2015-09-09
US201562216062P 2015-09-09 2015-09-09
US62/216,062 2015-09-09
US62/216,046 2015-09-09
US201562255294P 2015-11-13 2015-11-13
US62/255,294 2015-11-13
US201662323065P 2016-04-15 2016-04-15
US62/323,065 2016-04-15
PCT/US2016/050994 WO2017044780A1 (en) 2015-09-09 2016-09-09 Methods for combining adoptive t cell therapy with oncolytic virus adjunct therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021147640A Division JP2022003043A (ja) 2015-09-09 2021-09-10 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法

Publications (2)

Publication Number Publication Date
JP2018526428A true JP2018526428A (ja) 2018-09-13
JP2018526428A5 JP2018526428A5 (enExample) 2019-10-24

Family

ID=58240173

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018513549A Withdrawn JP2018526428A (ja) 2015-09-09 2016-09-09 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2021147640A Pending JP2022003043A (ja) 2015-09-09 2021-09-10 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2023176751A Pending JP2023176003A (ja) 2015-09-09 2023-10-12 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021147640A Pending JP2022003043A (ja) 2015-09-09 2021-09-10 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2023176751A Pending JP2023176003A (ja) 2015-09-09 2023-10-12 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法

Country Status (4)

Country Link
US (3) US20190038727A1 (enExample)
EP (1) EP3347473A4 (enExample)
JP (3) JP2018526428A (enExample)
WO (1) WO2017044780A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022003043A (ja) * 2015-09-09 2022-01-11 ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2024519428A (ja) * 2021-03-04 2024-05-14 ドイッチェス・クレープスフォルシュングスツェントルム Ｃａｒ操作ｔ細胞及びパルボウイルスｈ－１を含む癌療法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8052968B2 (en) 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
WO2017147553A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
EP4197551A3 (en) 2016-06-24 2023-10-25 McMaster University Adoptive cell transfer and oncolytic virus combination therapy
EP3577132A4 (en) 2017-02-03 2021-03-10 University of Pittsburgh - of The Commonwealth System of Higher Education ONCOLYTIC VIRUS THERAPY
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
US20220347244A1 (en) * 2018-01-19 2022-11-03 Kolon Life Science, Inc. Recombinant vaccinia virus and pharmaceutical composition comprising same
AU2019339535B2 (en) 2018-09-15 2025-11-20 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
EP3897846A1 (en) * 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
WO2020186355A1 (en) * 2019-03-20 2020-09-24 Turnstone Biologics Inc. Sequential heterologous boost oncolytic viral mmunotherapy
WO2020247547A1 (en) * 2019-06-03 2020-12-10 Geovax, Inc. Cancer vaccine compositions and methods for use thereof
BR112021022112A2 (pt) * 2019-06-05 2022-01-04 Laitram Llc Transportador espiral, correia transportadora espiral, e módulo de correia transportadora
CN110540960A (zh) * 2019-09-11 2019-12-06 苏州大学 结合有免疫检查点阻断剂的t淋巴细胞及其在制备抗肿瘤药物中的应用
WO2022057904A1 (zh) * 2020-09-18 2022-03-24 成都美杰赛尔生物科技有限公司 溶瘤病毒与经改造的免疫细胞联合治疗肿瘤
WO2024054293A1 (en) * 2022-09-08 2024-03-14 Research Institute At Nationwide Children's Hospital Oncolytic virus combination to maximize oncolytic activity
WO2024124190A1 (en) 2022-12-09 2024-06-13 Microbial Machines, Inc. Engineered microorganisms for delivery of therapeutic agents
WO2024259195A1 (en) * 2023-06-16 2024-12-19 Elias Animal Health Use of cd200ar-l for enhancing adoptive t-cell therapy
WO2024263805A1 (en) 2023-06-21 2024-12-26 Microbial Machines, Inc. Genetically engineered microorganisms for detection of diseased cells
CN118045162A (zh) * 2024-02-28 2024-05-17 北京景达生物科技有限公司 核心蛋白聚糖联合nk细胞在治疗实体瘤中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006409A1 (en) * 1999-10-05 2002-01-17 Wood Gary W. Composition and method of cancer antigen immunotherapy
US20110064650A1 (en) * 2008-05-16 2011-03-17 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2014170389A1 (en) * 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2406387A4 (en) 2009-03-09 2013-04-17 Tvax Biomedical I Llc CELL IMMUNOTHERAPY FOR INFECTION DISEASES
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3347473A4 (en) * 2015-09-09 2019-04-10 Tvax Biomedical I, LLC METHOD FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ATTACHMENT THERAPY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006409A1 (en) * 1999-10-05 2002-01-17 Wood Gary W. Composition and method of cancer antigen immunotherapy
US20110064650A1 (en) * 2008-05-16 2011-03-17 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2014170389A1 (en) * 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MELCHER A: "THUNDER AND LIGHTNING: IMMUNOTHERAPY AND ONCOLYTIC VIRUSES COLLIDE.", MOLECULAR THERAPY, vol. VOL:19,NR:6, JPN5018005938, 19 April 2011 (2011-04-19), pages 1008 - 1016, ISSN: 0004664409 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022003043A (ja) * 2015-09-09 2022-01-11 ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2023176003A (ja) * 2015-09-09 2023-12-12 ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
JP2024519428A (ja) * 2021-03-04 2024-05-14 ドイッチェス・クレープスフォルシュングスツェントルム Ｃａｒ操作ｔ細胞及びパルボウイルスｈ－１を含む癌療法

Also Published As

Publication number Publication date
JP2022003043A (ja) 2022-01-11
US20190038727A1 (en) 2019-02-07
EP3347473A4 (en) 2019-04-10
US11633442B2 (en) 2023-04-25
EP3347473A1 (en) 2018-07-18
US20230233631A1 (en) 2023-07-27
JP2023176003A (ja) 2023-12-12
US12419924B2 (en) 2025-09-23
WO2017044780A1 (en) 2017-03-16
US20200353002A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
US12419924B2 (en) Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy
US11124582B2 (en) FLT3L-FC fusion proteins
ES2686424T5 (es) Inmunoterapia con células alogénicas redireccionadas
US20250090560A1 (en) T cell receptors for immunotherapy
JP7339944B2 (ja) がんの処置におけるｃａｒ－ｔ細胞またはｃａｒ－ｎｋ細胞を用いるｌｉｌｒｂ４のターゲティング法
KR20190130624A (ko) 세포 면역치료요법 전 세포독성 사전컨디셔닝의 대체
CA3070998A1 (en) Enhanced chimeric antigen receptors and use thereof
JP2021522208A (ja) ＣＤ８ａｂおよびクラス１制限Ｔ細胞受容体の強制発現による細胞傷害性ＣＤ８細胞へのＣＤ４ Ｔ細胞の再プログラミング
JP2024514203A (ja) Ｃｄ５陽性がんを標的とするキメラ抗原受容体
CN106459991A (zh) 新型药剂及其用途
US10821134B2 (en) BK virus specific T cells
JP2022513076A (ja) Ｃａｒおよびｔｃｒ形質導入用のモジュール式ポリシストロニックベクター
CA3191390A1 (en) Modified b cells and methods of use thereof
TW202444896A (zh) 多受體自然殺手細胞
WO2025259866A2 (en) Combination of chemotherapy, cancer cell vaccine and adoptive cell therapy
US20230255978A1 (en) Methods for treating glioblastoma
WO2024259195A1 (en) Use of cd200ar-l for enhancing adoptive t-cell therapy
JP2025531419A (ja) 免疫療法のエンハンサーとして有用なｉｌ－２１融合タンパク質
WO2025184411A1 (en) Serum-resistant eev viruses and uses thereof
TW202132326A (zh) Hla限制性hormad1 t細胞受體及其用途
HK40030417B (zh) 用於免疫疗法的t细胞受体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210910

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211124

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211130

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211217

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211221

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220113